62. Paroxysmal nocturnal hemoglobinuria Clinical trials / Disease details


Clinical trials : 292 Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05476887
(ClinicalTrials.gov)
November 25, 202225/7/2022To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104An Open-label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-naïve Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaDrug: KP104Kira Pharmacenticals (US), LLC.NULLRecruiting18 YearsN/AAll35Phase 2China
2NCT05490017
(ClinicalTrials.gov)
December 30, 20204/8/2022To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104SYNERGY-1: A Phase 1 First-in-human, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104 in Healthy SubjectsParoxysmal Nocturnal HemoglobinuriaDrug: KP104;Drug: PlaceboKira Pharmacenticals (US), LLC.NULLCompleted18 Years55 YearsAll80Phase 1Australia